IMPORTANCE Sebaceous neoplasms (SNs) define the Muir-Torre syndrome variant of Lynch syndrome (LS), which is associated with increased risk for colon and other cancers necessitating earlier and more frequent screening to reduce morbidity and mortality. Immunohistochemical (IHC) staining for mismatch repair (MMR) proteins in SNs can be used to screen for LS, but data on subsequent germline genetic testing to confirm LS diagnosis are limited.
line mutations in MMR genes, further defining MTS as a clinical variant of LS.
Identification of patients with LS is clinically valuable given availability of risk-reducing strategies, including earlier and more frequent colonoscopy and prophylactic hysterectomy and bilateral salpingo-oophorectomy, to reduce cancer-related morbidity and mortality. 5, 6 Routine screening of colorectal and endometrial cancers for evidence of MMR deficiency, including presence of microsatellite instability (MSI) and/or absent expression of the MMR proteins by immunohistochemical (IHC) analysis, has shown that 2% to 4% of colorectal cancers and 1% to 5% of endometrial cancers are associated with LS. 7, 8 This universal tumor-screening approach has better sensitivity than clinical criteria for identifying patients with LS and has the potential to be cost-effective if individuals and their at-risk relatives can be identified and screened to reduce morbidity and mortality. 9 Given the experience with colorectal and endometrial cancers, routine screening of SNs for MMR deficiency to identify LS has been proposed. [10] [11] [12] Several studies have examined the use of MSI and IHC testing to screen unselected SNs and have shown prevalence of MMR deficiency ranging from 25% to 60%. [11] [12] [13] [14] [15] [16] However, most of these studies had limited or no information on germline genetic test results; thus, data regarding the prevalence of germline MMR mutations confirming LS among individuals with SNs, as well as sensitivity and specificity of SN tumor testing, are limited. Our objective was to characterize the utility of MSI and IHC screening of SNs in identification of germline MMR mutations confirming LS. We analyzed data on all patients with SNs evaluated at 2 large clinical cancer genetics programs to examine outcomes of tumor screening and germline genetic testing.
Methods
Permission for research was approved by the institutional review boards of the University of Michigan Comprehensive Cancer Center (UMCCC) and the Dana-Farber Cancer Institute (DFCI). Patients provided written consent to participate in DNAbanking registries, granting access to deidentified medical and family history and use of this information for publication. Participants were identified through review of patients enrolled in research registries of the cancer genetics clinics at UMCCC and DFCI from January 2000 through September 2012. Individuals with diagnoses of sebaceous carcinoma, sebaceous adenoma, sebaceoma, and sebaceous epithelioma were included in the analysis; patients with sebaceous hyperplasia were excluded. Nine patients presenting on the basis of SN diagnosis were found to carry MMR mutations without any testing of their SN tumors. Reasons that testing of SNs was not completed included known MMR mutation in the family (3 of 9), tumor testing performed on a different LS-related tumor (4 of 9), and family history meeting Amsterdam I or II clinical diagnostic criteria warranting direct germline genetic testing (2 of 9).
The remaining 77 patients underwent tumor analysis for MMR deficiency on a single SN. The MSI testing could not be completed in 37 SN tumors (48%) because of insufficient sample (individual MSI results are reported in Table 1 and  Table 2 ); IHC analysis was completed on all 77 SN tumors. Immunohistochemical analysis revealed that 38 of 77 SNs (49%) had absent expression of 1 or more MMR proteins. Twenty-seven had absent expression of MSH2 or MSH2/MSH6; 9 (33%) of these were found to carry germline MSH2 mutations. Nine had absent expression of MLH1 or MLH1/PMS2; 4 (44%) of these had germline MLH1 mutations. Two patients had equivocal IHC staining for MSH6 only; 1 had a pathogenic MSH6 mutation and 1 had a VUS in MSH6. None of the samples demonstrated isolated absence of PMS2 expression. In total, 14 of 38 patients with abnormal IHC test results on SN were confirmed to carry pathogenic germline MMR mutations, for a positive predictive value of 37% for IHC screening (Figure, Table 1, Table 2 ). Several significant differences were noted between those with pathogenic germline MMR mutations (n = 25) and those with abnormal IHC expression but without germline MMR mutations (n = 23) ( Table 3) . Mean age at diagnosis of SN among mutation carriers was significantly younger than in those without mutations (54.8 vs 67.2 years; P < .001, t test). Patients with MMR mutations were significantly more likely to have more than 1 SN (40% vs 0%; P < .001, Fisher exact test), and 10 of 12 patients (83%) with more than 1 SN had pathogenic germline MMR mutations, making this a strong predictor of mutation status. One patient with more than 1 SN had a VUS in MSH6. Family history differences, as measured by adherence to clinical diagnostic family history criteria and risk model scores, were also noted. Of patients with MMR mutations, 48% met Amsterdam I or II criteria, compared with 4% in the group without mutations (P < .001). Among individuals with family his- dergo germline genetic testing of all MMR genes because of suspicious personal or family histories. Two of these 11 patients (18%) were found to carry germline mutations: 1 pathogenic mutation in MSH2 and 1 suspected pathogenic mutation in PMS2 (Table 1) . One patient had a VUS in MSH2. Twenty-eight 16 and would have identified 6 of 16 mutation carriers (38%) in this series. A PREMM 1,2,6 risk model threshold of greater than 5% has been suggested for consideration of germline testing 22 and would have identified 10 carriers (62%). Whereas a detailed pedigree including thirddegree relatives and incorporating all cancer diagnoses remains useful to help interpret IHC test results, the low sensitivity of family history alone limits its utility as a prescreen to select patients for IHC screening. The majority (61%) of patients with abnormal IHC test results in an SN had no germline mutation identified, indicating that MMR phenotype in SNs is not diagnostic of LS. This is particularly striking in the subgroup of patients with absent MSH2/ MSH6 expression in SNs, of whom only 33% had germline MSH2 mutations and no TACSTD1/EPCAM mutations were identified (Figure) . In colorectal and endometrial cancer, absent MSH2/ MSH6 staining is widely considered to be diagnostic of LS, with 85% of patients having identifiable germline MSH2 or TACSTD1/ EPCAM mutations. 23, 24 These results suggest that a substantial number of patients with abnormal IHC test results but without germline MMR mutations could have developed SN through somatic, nonheritable molecular events. Caution should be used in interpreting the clinical implications of abnormal IHC test results in SN in the absence of germline genetic test results.
We acknowledge that our study has certain limitations. Patients were evaluated through 2 different clinics over a 12-year period, with variability in referral practices and in clinical testing practices and standards. Germline genetic testing was completed in only 11 of 39 patients (28%) with normal IHC test results. Without confirmation of normal germline results, specificity cannot be accurately estimated and sensitivity may be overestimated because unidentified mutation carriers could exist in the untested group with normal IHC test results. However, mean age at diagnosis of SN and strength of family history as measured by PREMM 1,2,6 scores among patients with normal IHC test results who did not undergo germline testing did not differ significantly from the characteristics of the tested group who did not carry germline mutations (Table 3) . It is also possible that some patients with abnormal IHC test results but no germline mutations may have a germline mutation that could not be identified with currently available testing. Mutation carriers had earlier onset of SN, higher prevalence of multiple SNs, and stronger family histories and risk model scores compared with patients with abnormal IHC test results and no germline mutation found (Table 3) . Finally, this series represents a selected population of patients who were identified as having risk for MTS and referred for clinical genetics evaluation at tertiary referral centers, sometimes solely on the basis of SN and sometimes because of additional suggestive personal or family history. There are institutional differences in patient demographic characteristics and referral patterns, and this series does not represent a universal screening approach. Defining the true prevalence of LS among all patients with SNs will require additional prospective study. However, our finding of MMR gene mutations in nearly 1 in 3 patients presenting on the basis of SNs reinforces the importance of collaboration among specialists in dermatology, pathology, and clinical genetics to ensure genetic referral for these individuals.
Conclusions
We propose a clinical practice algorithm for patients with SN (Box) to optimize identification of LS after diagnosis of sebaceous adenoma or carcinoma, beginning with consideration of IHC screening of SNs to be ordered by pathologist or clinician, excluding patients with sebaceous hyperplasia or known LS diagnosis. Family history screening for LS-associated cancers in at least first-degree and second-degree relatives is also warranted for all patients with SN. Genetics referral should be recommended for patients with SN and any of the following: absent MMR protein expression (abnormal result) on IHC screen, normal MMR protein expression and personal or family history of any LS-associated cancer, or more than 1 SN. Our findings suggest that a combination of routine tumor testing and family history assessment would optimize identification of patients with LS in the dermatology setting. 
